Backed by Cultivation Capital, Cardialen enters human clinical trials

By Brian Feldt, St. Louis Business Journal

Cardialen, a medical device company based out of St. Louis, began its first human clinical trials for its heart therapy device last month.

Cardialen has developed an irregular heartbeat treatment that is designed to keep the heart in a normal rhythm in the long term, slowing the progression of atrial fibrillation (AF), a common type of cardiac arrhythmia.

The company has raised more than $7 million to date, including a $2.5 million Series A financing, which included $500,000 from St. Louis-based Cultivation Capital in January.

St. Louis Business Journal